Sunshield Q2 FY27: PAT down 22% YoY to ₹5.6 Cr despite 32% revenue growth, margins compress
PAT -21.99% YoY · revenue +31.77% · margins compressing
₹161.29 Cr
+31.77% YoY
₹5.64 Cr
-21.99% YoY
3.48%
-2.4pp YoY
₹6.41
Sunshield Chemicals' standalone net profit for Q2 FY27 (quarter ended September 30, 2026) fell 22% year-on-year to ₹5.64 Cr, even as revenue from operations grew 31.8% YoY to ₹161.29 Cr. Profit also dropped 58.2% sequentially from ₹13.49 Cr in Q1 FY27, despite revenue rising 26.5% quarter-on-quarter — a clear divergence between topline growth and bottom-line delivery. Basic EPS came in at ₹6.41 for the quarter versus ₹9.69 a year ago and ₹15.34 last quarter.
Q2 FY-2027 vs prior quarters
The gap is entirely a margin story: operating margin (EBITDA/revenue) compressed to roughly 6.1% from 11.45% in Q2 FY26 and 16.05% in Q1 FY27, and net margin fell to about 3.5% from 5.89% YoY and 10.51% QoQ. Combined material and traded-goods costs — cost of materials consumed, purchase of stock-in-trade and the change in inventories — rose to roughly 84% of revenue, up from about 76% a year ago and 70% last quarter. The swing is driven chiefly by purchase of stock-in-trade, which jumped to ₹24.27 Cr from just ₹0.09 Cr in Q2 FY26 and ₹10.45 Cr in Q1 FY27, pointing to a much larger share of lower-margin traded (versus manufactured) goods in this quarter's sales mix.
The stock went into the print at ₹1,045, down 5.6% over the past month of trading.
For context: revenue is at a 6-quarter high.
There is no prior management guidance or concall commentary on record for this filing, and no analyst/brokerage preview could be located for this specific quarter, so both the guidance and street comparisons are unknown rather than a miss or beat. The result follows a strong Q1 FY27 in which standalone PAT had nearly doubled YoY on sharp margin expansion — a base effect that makes the sequential slowdown look sharper than it otherwise would, though the YoY profit decline remains the primary signal here. No deals, capex or management changes were disclosed alongside this filing beyond the routine Board approval of the unaudited results on November 5, 2026, with auditors CNK & Associates issuing an unmodified limited-review report; a management press release was not available for this filing, so the company's own framing could not be cross-checked.
W1
Whether OPM recovers toward the 11-16% range seen in the prior two quarters as the traded-goods (purchase of stock-in-trade) mix normalises.
W2
Working-capital trend — trade receivables (₹105.27 Cr) and inventories (₹71.44 Cr) and whether H2 FY27 operating cash flow turns positive again.
W3
No formal management guidance is on record; the Q3 FY27 print will show whether this quarter's margin compression was transient or structural.
Single-segment standalone filer, no consolidated statement; arithmetic ties out exactly (totalIncome, PAT checks). Unaudited, limited-review report unmodified. H1 operating cash flow swung negative on working-capital build.